Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients With Advanced Gastric and Gastroesophageal Cancer

Next Previous
Trial Profile

A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients With Advanced Gastric and Gastroesophageal Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BDC 4182 (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; First in man
  • Sponsors Bolt Biotherapeutics

Most Recent Events

  • 04 May 2025 Status changed from not yet recruiting to recruiting.
  • 15 Apr 2025 Status changed from planning to not yet recruiting.
  • 24 Mar 2025 According to a Bolt Biotherapeutics media release, company is Finalizing preparations for this trial.dose escalation trial is planned to start in Australia in the second quarter of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top